Central Bank & Trust’s Core Laboratories CLB Stock Holding History

Central Bank & Trust’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-214	Closed	-$8K	–	254
2019 Q4	$8K	Buy	+214	New	+$9.62K	﹤0.01%	237

Other funds holding CLB

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Central Bank & Trust's CLB Position: Q1 2020 in Review

Central Bank & Trust sold out of Core Laboratories (CLB) in Q1 2020, closing a stake of 214 shares — an estimated $8K sold.

Central Bank & Trust first reported a position in CLB in Q4 2019 and held it in 1 quarter. The position peaked at $8K in Q4 2019. 207 funds tracked by Wall St. Rank hold CLB as of Q1 2020.

Central Bank & Trust reported no remaining Core Laboratories position as of Q1 2020 after selling out during the quarter.
Central Bank & Trust sold 214 Core Laboratories shares in Q1 2020, an estimated $8K.
Central Bank & Trust first reported a position in Core Laboratories in Q4 2019 and held it in 1 quarter.
Central Bank & Trust's Core Laboratories position peaked at $8K in Q4 2019.
207 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2020.

Based on Central Bank & Trust's 13F filing for Q1 2020, filed 14 Apr 2020.